Seasoned life science equity analyst, Chad Messer, Ph.D., has joined Lake Street Capital Markets as a managing director of equity research.
Based in New York, Dr. Messer has over two decades of experience spanning equity research, investor relations, and biotechnology.
Most recently, he served as vice president of investor relations at Cullinan Therapeutics (NASDAQ: CGEM), where he spearheaded investor outreach and messaging and helped advise corporate finance activities, including a successful $280 million PIPE financing. Prior to this, he was a covering biotech equity analyst for over 15 years at Needham & Company and Piper Jaffray. Dr. Messer holds a Ph.D. in Pharmacology from Yale University and an MBA from NYU’s Leonard N. Stern School of Business.
In a statement, Mark Argento, president and head of institutional equity at Lake Street Capital Markets, said Dr. Messer’s “deep understanding of the biotechnology sector and extensive track record in equity research make him an invaluable addition to our team.”
